THE BIOTECH GROWTH TRUST PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 937 GBX | +1.19% |
|
+0.64% | +4.81% |
| 26/03 | Biotech Group Acquisition Withdraws IPO | DJ |
| 2023 | Biotech Growth's total return underperforms benchmark in tough market | AN |
| Sales 2022 | -205M -256M -21.35B | Sales 2023 | -32.42M -40.49M -3.38B | Capitalization | 303M 379M 31.59B |
|---|---|---|---|---|---|
| Net income 2022 | -202M -252M -21.04B | Net income 2023 | -41M -51.22M -4.27B | EV / Sales 2022 | -1.96 x |
| Net Debt 2022 | 31.74M 39.65M 3.31B | Net Debt 2023 | 17.4M 21.73M 1.81B | EV / Sales 2023 | -9.89 x |
| P/E ratio 2022 |
-1.84
x | P/E ratio 2023 |
-7.64
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.66% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.19% | ||
| 1 week | +0.64% | ||
| Current month | -5.83% | ||
| 1 month | -5.07% | ||
| 3 months | +2.52% | ||
| 6 months | +29.42% | ||
| Current year | +4.81% |
1 week
924.00
969.00
1 month
922.001 000.00
Current year
857.161 034.00
1 year
715.001 034.00
3 years
715.001 484.00
5 years
660.381 750.00
10 years
424.061 750.00
| Members of the board | Title | Age | Since |
|---|---|---|---|
Geoffrey Hsu
BRD | Director/Board Member | - | 16/18/16 |
Roger Yates
CHM | Chairman | 67 | 01/21/01 |
Steve Bates
BRD | Director/Board Member | 66 | 08/15/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 937 | +1.19% | 32,552 |
| 25/24/25 | 926 | -2.53% | 48,374 |
| 24/24/24 | 950 | -0.21% | 51,910 |
| 23/24/23 | 952 | +2.92% | 53,195 |
| 22/24/22 | 925 | -0.64% | 58,909 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotes
The Biotech Growth Trust PLC is a United Kingdom-based investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies. The Company invests approximately 10% in aggregate of the value of its gross assets in other closed-ended investment companies, including investment trusts listed on the London Stock Exchange. The Company invests approximately 15% of the value of its gross assets in any one individual stock at the time of acquisition. Its portfolio of investments across various countries includes Netherlands, the United States of America, Canada, and China. The Companyâs alternative investment fund manager is Frostrow Capital LLP.
Sector
Investment Trusts
Calendar
14/11/2024
- Q2 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.37
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +4.81% | 390M | |
| +3.27% | 14.32B | |
| +3.12% | 6.21B | |
| +12.72% | 4.4B | |
| +10.97% | 4.36B | |
| -7.52% | 4B | |
| +3.61% | 3.51B | |
| +8.55% | 3.22B | |
| +7.91% | 3.06B | |
| -1.91% | 2.77B |
- Stock Market
- Equities
- BIOG Stock
